Comparison between the AZISAST and AMAZES trials
| Population | Intervention | Follow-up | Patients intervention/control | Primary outcomes | |
| Brusselle et al (AZISAST)30 | 18–75 years GOLD step 4/5 >1000 µg fluticasone or equivalent 2 exacerbations requiring OCS in past 12/12 FeNO in normal limits | Azithromycin 250 mg thrice weekly | 26 weeks | 109 55/54 | Exacerbation rate |
| Gibson et al (AMAZES)40 | 18 years or older Diagnosis of asthma (post-bronchodilator reversibility >12%/airway hyper-responsiveness or PEFR variability >12%) Partial loss of asthma control—ACQ≥0.75 | Azithromycin 500 mg thrice weekly | 48 weeks | 420 213/207 | Exacerbation rate |
ACQ, Asthma Control Questionaire; GOLD, Global Initiative for Chronic Obstructive Lung Disease; OCS, Oral corticisteroids; PEFR, Peak Expiratory Flow Rate.